Abbott Laboratories (NYSE:ABT) recently announced promising results from its AVEIR Conduction System Pacing study, showcasing its innovative leadless pacemaker technology. Over the last quarter, the ...

While J&J, Abbott and Boston Scientific have all said the White House’s tariff policies will cost them hundreds of millions ...

Abbott has reported new data from its Volt CE Mark Study in individuals treated with PFA therapy using the Volt PFA System ...

PFA therapy works differently from traditional cardiac ablation approaches by delivering high energy electrical pulses to targeted areas of cardiac t ...

Abbott (NYSE: ABT) today announced new study data demonstrating the safety and efficacy of its Volt pulsed field ablation ...

Thanks to healthcare reform, the hurdles to securing reimbursement and technology add-on payments have risen. Boston will need to invest more in clinical studies to demonstrate superiority of outcomes ...

Q1 2025 Earnings Call Transcript April 16, 2025 Abbott Laboratories beats earnings expectations. Reported EPS is $1.09, ...

Abbott's diversified global supply chain and 25 new products in the pipeline position it well to navigate tariff impacts and ...

Abbott designed the Volt PFA catheter for maneuverability, efficient ablation and thermal risk mitigation, said Dr.

CEO Robert Ford noted that Abbott has 90 manufacturing locations worldwide, with plants close to customers, redundancy, and ...